Lacoste Jeans Mens
Apogenix, a spin out from the German Cancer Research Center (DKFZ), is developing novel protein therapeutics for the treatment of cancer and inflammatory diseases based either on the targeted modulation of apoptosis (programmed cell death) or on blocking the growth of tumor cells. The company's lead product candidate APG101 is being developed for the treatment of Glioblastoma Multiforme (GBM), the most common and aggressive type of primary brain tumor. Since its inception in 2005, the company has raised more than 50 million with dievini Hopp BioTech Holding GmbH Co. KG as main investor, and has been awarded public grants totaling over 8 million. Apogenix is based in Heidelberg, Germany.
The leading edge Biotech Cluster Rhine Neckar (BioRN cluster) has a focus on personalized medicine and cancer research. The BioRN cluster strives to occupy one of Europes top positions in the areas of personalized medicine and cancer.
Cancer Research Center (DKFZ), is developing novel protein therapeutics for the treatment of cancer and inflammatory diseases based either on the targeted modulation of apoptosis (programmed cell death) or on blocking the growth of tumor cells. The company's lead product candidate APG101 is being developed for the treatment of Glioblastoma Multiforme (GBM), the most common and aggressive type of primary brain tumor. Since its inception in 2005, the company has raised more than 50 million with dievini Hopp BioTech Holding GmbH Co. KG as main investor, and has been awarded public grants totaling over 8 million. Grants to Bring Next Generation Sequencing Diagnostics to the Clinic
About the Biotech Cluster Rhine Neckar
December 2009, Apogenix started a controlled phase II trial with APG101 Mens Lacoste
Dr Thomas Hger, CEO/CFO of Apogenix commented: "This grant, along with the grants we have been awarded over the last five years totaling more than 6 million, plays a substantial role in the development of our lead substance APG101 for the treatment of life threatening diseases with a high unmet medical need. We are happy that we have received one of the highest BMBF grants as partner of the Biotech Cluster Rhine Neckar. This allows us to develop APG101 for a new, promising indication, namely MDS. We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof of concept in a phase II trial planned for 2013."
Apogenix Receives Additional 2 3 Million BMBF Grant as Partner of the Biotech Cluster Rhine Nec
Apogenix Provides Update in the Ongoing Phase II Clinical Trial of APG101 to Treat Glioblastoma Muscular Dystrophy Association Awards $1 Million to Tivorsan Pharmaceuticals, Inc. for Accelerating Pivotal Pre Clinical Work on TVN 102 as a Potential Muscular Dystrophy Treatment
for the treatment of Glioblastoma Multiforme. The patient recruitment for this study was completed in September 2011. Apogenix was Lacoste Jeans Mens granted orphan drug designation for APG101 in 2009 for the treatment of GBM in Europe and in the US.
The company's lead product candidate, APG101, a first in class, fully human, soluble fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG, successfully completed a phase I study in 2009. In Lacoste Polo Outlet Sale
Apogenix, a spin out from the German Lacoste Polo Shirts Uk Cheap
Apogenix: Death Receptor CD95 Promotes Tumour Growth Massachusetts Life Sciences Center Launches Third Year of Small Business Matching Grant Program
Heidelberg, January 3, 2012 The biopharmaceutical company Apogenix GmbH today announced that it has received an additional 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a biomarker program.
Myelodysplastic syndromes are a diverse collection of hematological (blood related) medical conditions that involve ineffective production of blood cells in the bone marrow of MDS patients. Hence, they are no longer able to produce mature, functionally active blood cells which regularly leads to anemia. This is normally treated by blood transfusions which can, however, result in an iron overload of the organism frequently associated with liver damage. As the disease progresses, MDS patients often suffer from infections and sudden bleedings which can lead to death.
APG101 is a first in class, fully human protein that provides an innovative therapeutic approach to treating solid tumors such as Glioblastoma Multiforme (GBM). APG101 is the most advanced inhibitor of the CD95 ligand (CD95L) in clinical development. In September 2011, Apogenix announced the completion of patient recruitment of its phase II clinical trial in GBM. Final results of this trial are expected in the first quarter of 2012.
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma $1 Million in North Carolina Biotechnology Center Grants Fund Basic Research
Lacoste Jeans Mens
Ghd Straighteners John Lewis
Lacoste T Shirt Sale
Women's Pique Polo Shirts Uk
Embroidered Polo Shirts Cheap Uk
Fred Perry Dress
Mens Fred Perry
Lacoste Yellow Shirt
Lacoste Sport Polo Shirt Junior
Lacoste Polo Shirts Online
Xxl Polo T Shirts Online India
Babyliss Curling Wands
Beats Monster Studio Fake
Us Polo T Shirts Online Purchase
Clarisonic Mia 2 Charger
Ghd Hair Brush